Professor Patrick Kennedy areas of expertise:

Professional statement

Professor Patrick Kennedy is a leading London-based consultant physician and hepatologist, whose work in viral liver disease is known internationally.

Professor Kennedy trained at University College Dublin. Upon completion of his initial medical training, he undertook post-graduate training in London and was subsequently appointed as a senior lecturer at Barts and The London School of Medicine and Dentistry in 2009.

Professor Kennedy has a special interest in the management of liver disease in young people, working closely with premiership football clubs and managing liver disease in professional sports people and elite athletes from the UK and abroad.

He has produced novel work redefining disease phase in chronic hepatitis B (CHB). The main focus of his curent research work is around broadening treatment candidacy and the development of individualised treatment strategies for viral liver disease. He is widely published in the field of hepatology, with over 200 publications and 90 peer-reviewed articles, in addition to multiple book chapters, he has also edited a textbook of hepato-gastroenterology.

Additionally, Professor Kennedy is an expert advisor for the WHO and is part of the HBV clinical guideline development group. He is also a member of the European Association for the study of the liver (EASL) HBV clinical practice guidelines and has served as a member for NICE on the viral hepatitis clinical guideline committee.

Furthermore, Professor Kennedy provides expert opinion for the United Kingdom Advisory Panel (UKAP) on blood-borne viruses and is the current chair of the British Viral Hepatitis Group and former Lead for the British Association for the Study of the Liver (BASL) HBV special interest group. He works closely with industry and provides expert opinion on drug development programmes.

He is the principal Investigator for a number of investigator-led and commercial phase 1, 2 and 3, clinical trials of novel therapies in viral liver disease. At present, he leads studies on the development of novel therapies in HBV and hepatitis delta virus (HDV). In addition, he is passionate about patient education and ensuring patients play a central role in their own management. Professor Kennedy has developed HBV&Me, a management app, and a current area of his research is expanding the utility of patient management tools to improve care.

Videos of doctor

Fibroscan for assessment of liver disea...

View all videos by Professor Patrick Kennedy

Doctor's articles

A doctor standing beside a big liver diagram.

FibroScan FAQ: Your questions answered

Read all articles by Professor Patrick Kennedy

Credentials

GMC: ‍4500195

Professional experience

• More than 25 years of experience
• Consultant Gastroenterologist and Hepatologist, London Liver Group (present)
• Consultant Gastroenterologist and Hepatologist, Hospital of St John and St Elizabeth (present)
• Consultant Gastroenterologist and Hepatologist, King Edward VII Hospital (present)
• Consultant Gastroenterologist and Hepatologist and Reader in Hepatology, Barts and the London NHS Trust (present)
• Hepatology Lead for the Gastroenterology and Hepatology Section, Royal Society of Medicine (present)
• Locum Consultant Hepatologist/Gastroenterologist Imperial College NHS Trust (2008 - 2009)
• London Hepatology Training Scheme-SpR Liver Intensive Care/Transplant Medicine, King's College Hospital NHS Foundation Trust (2007)
• London Hepatology Training Scheme - SpR Hepatology, St Mary's Hospital, Imperial College NHS Trust (2006 - 2007)
• SpR Gastroenterology/General Internal Medicine Northwest Thames SpR Gastroenterology/General Internal Medicine Training Scheme (2001 - 2007)
• SpR Gastroenterology/General Internal Medicine King's College Hospital NHS Foundation Trust (2000)
• Senior House Officer - Medical Rotation King's College Hospital NHS Foundation Trust (1998 - 2000)
• House Officer University College Dublin (1996 - 1998)

...

Sub-specialties

• Liver disease
• Abnormal liver function
• Viral hepatitis
• Fatty liver disease
• Alcohol related liver disease
• Abdominal pain

...

Positions in public associations

• British Viral Hepatitis Group (BVHG) Chair
• Member National Strategic Group in Viral Hepatitis
• United Kingdom Advisory Panel for bloodborne viruses
• BASL special interest group (SIG) lead for HBV
• Barts Health NHS Trust – Viral Hepatitis Lead
• Quality Standard Committee for Chronic Hepatitis B
• Member of Advisory Group panel for Chronic Hepatitis B – National Institute of Health and Clinical Excellence
• Key Opinion Leader and Member of Global Expert Advisory Panels
• European Association for the Study of the Liver: Faculty member
• Editor for Journal of Viral Hepatitis
• Editorial Board- Journal of Hepatology, Gut and Gastroenterology
• Chair of the Gastroenterology sub-board, Blizard Institute, QMUL
• Former Hepatology Lead, Royal Society of Medicine, UK
• Lead for viral liver disease Bart’s Health NHS Trust

...

Teaching posts

• Professor & Honorary Consultant Hepatologist, Queen Mary University of London & Barts and The London NHS Trust (Tenure University Post) (present)
• Reader & Honorary Consultant Hepatologist, Barts and The London SMD, QMUL.(2016 - 2019)
• HEFCE Senior Lecturer & Honorary Consultant Hepatologist, Barts and The London SMD, QMUL (2009 - 2016)

...

Education

• Undergraduate medical training at University College Dublin (1996)
• Post-graduate medical training in gastroenterology and hepatology, London
• Doctorate research, The Institute of Hepatology, University College London (2006)

...

Publications and conferences

• Professor Kennedy is widely published on ResearchGate.
• Has produced novel work redefining disease classification and investigating the role of individualised treatment strategies for chronic hepatitis B
• Has written several book chapters on hepatology
• Has editied his own book on hepatogastroenterology
• Koffas A, Kumar M, Gill US, Jindal A, Kennedy PTF*, Sarin SK*. Chronic hepatitis B: the demise of the 'inactive carrier' phase. Hepatol Int. 2021 Feb 27.
• Svicher V*, Salpini R*, Piermatteo L, Carioti L, Battisti A, Colagrossi L, Scutari R, Surdo M, Cacciafesta V, Nuccitelli A, Hansi N, Ceccherini Silberstein F, Perno CF, Gill US, Kennedy PTF. Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B. Gut. 2020 Dec 21:gutjnl-2020-323300.
• Zeng G, Gill US, Kennedy PTF. Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis. Gut. 2020 Nov;69(11):1907-1912
• Le Bert N*, Gill US*, Hong M*, Kunasegaran K, Tan DZM, Ahmad R, Cheng Y, Dutertre CA, Heinecke A, Rivino L, Tan A, Hansi NK, Zhang M, Xi S, Chong Y, Pflanz S, Newell EW, Kennedy PTF*, Bertoletti A*. Effects of Hepatitis B Surface Antigen on Virus-specific and Global T Cells in Patients With Chronic HBV infection. Gastroenterology. 2020 Aug;159(2):652-664.
• Avellon A, Ala A, Diaz A, Domingo D, Gonzalez R, Hidalgo L, Kooner P, Loganathan S, Martin D, McPherson S, Munoz-Chimeno M, Ryder S, Slapak G, Ryan P, Valbuena M, Kennedy PT. Clinical Performance of DetermineTM HBsAg 2 rapid test for hepatitis B detection. J Med Virol. 2020 Apr 9.
• Koffas A, Petersen J, Kennedy PT. Reasons to consider early treatment in chronic hepatitis B patients. Antiviral Res. 2020 May;177:104783.
• Bertoletti A, Gill US, Kennedy PTF. Early treatment in chronic hepatitis B in children: Everything to play for? J Hepatol. 2020 Apr;72(4):802-803.
• Dolman GE, Kennedy PTF. Hepatitis B reactivation: reducing the risk in patients with inflammatory bowel disease. Gut. 2020 Jan 30. pii: gutjnl-2019-319480
• Gill US, Battisti A, Kennedy PTF. Emerging tools in the changing landscape of chronic hepatitis B management. Expert Rev Anti Infect Ther. 2019 Dec;17(12):943-955.
• Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. J Hepatol. 2020 Mar;72(3):539-557
• Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology. 2019 Nov 12.
• Bénéchet AP, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, Fumagalli V, Lusito E, Moalli F, Bianchessi V, Andreata F, Zordan P, Bono E, Giustini L, Bonilla WV, Bleriot C, Kunasegaran K, Gonzalez-Aseguinolaza G, Pinschewer DD, Kennedy PTF, Naldini L, Kuka M, Ginhoux F, Cantore A, Bertoletti A, Ostuni R, Guidotti LG, Iannacone M. Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature. 2019 Oct;574(7777):200-205.
• Le Bert N, Salimzadeh L, Gill US, Dutertre CA, Facchetti F, Tan A, Hung M, Novikov N, Lampertico P, Fletcher SP, Kennedy PTF, Bertoletti A. Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B. J Hepatol. 2020 Jan;72(1):34-44
• Bertoletti A, Kennedy PT. HBV antiviral immunity: not all CD8 T cells are born equal. Gut. 2019 Jan 30. pii: gutjnl-2018-317959. doi: 10.1136/gutjnl-2018-317959.
• Khakpoor A, Ni Y, Chen A, Ho ZZ, Oei V, Yang N, Giri R, Chow JX, Tan AT, Kennedy PT, Maini M, Urban S, Bertoletti A. Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection. J Virol. 2019 Feb 5;93(4). pii: e01457-18. doi: 10.1128/JVI.01457-18.
• Gill US*, Pallett LJ*, Thomas N, Burton AR, Patel AA, Yona S, Kennedy PT* & Maini MK*. Fine needle aspirates comprehensively sample intrahepatic immunity. Gut 2018 Nov 28. pii: gutjnl-2018-317071. doi: 10.1136/gutjnl-2018-317071.
• Gill US, Kennedy PTF. The impact of currently licensed therapies on viral and immune responses in Chronic Hepatitis B: considerations for future novel therapeutics. J Viral Hepat. 2019 Jan;26(1):4-15. doi: 10.1111/jvh.13040
• Lampertico P, Messinger D, Cornberg M, Brunetto M, Petersen J, Kennedy PT, Asselah T, Rothe V, Caputo A, Bakalos G, Pavlovic V, Papatheodoridis GV. A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B. Ann Gastroenterol. 2018 Nov-Dec;31(6):712-721. doi: 10.20524/aog.2018.0300. Epub 2018 Jul 26.
• Otano I, Escors D, Schurich A, Singh H, Robertson F, Davidson BR, Fusai G, Vargas FA, Tan ZMD, Aw JYJ, Hansi N, Kennedy PT, Xue SA, Stauss HJ, Bertoletti A, Pavesi A, Maini MK. Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Mol Ther. 2018 Nov 7;26(11):2553-2566. doi: 10.1016/j.ymthe.2018.08.013.
• Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PT, Gill US, Mauri C, Blair PA, Pelletier N, Maini MK. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest. 2018 Oct 1;128(10):4588-4603. doi: 10.1172/JCI121960.
• Salimzadeh L, Le Bert N, Dutertre CA, Gill US, Newell EW, Frey C, Hung M, Novikov N, Fletcher S, Kennedy PT, Bertoletti A. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest. 2018 Oct 1;128(10):4573-4587. doi: 10.1172/JCI121957.
• Koffas A, Dolman GE, Kennedy PT. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. Clin Med (Lond). 2018 Jun;18(3):212-218. doi: 10.7861/clinmedicine.18-3-212.
• Dolman GE, Koffas A, Mason WS, Kennedy PT. Why, who and when to start treatment for chronic hepatitis B infection. Curr Opin Virol. 2018 Jun;30:39-47. doi: 10.1016/j.coviro.2018.03.006.
• Gill US, Pallett LJ, Kennedy PT, Maini MK. Liver sampling: a vital window into HBV pathogenesis on the path to functional cure, Gut 2018 Apr;67(4):767-775. doi: 10.1136/gutjnl- 2017-314873
• Rivino L*, Le Bert N*, Gill US, Kunasegaran K, Cheng Y, Tan DZ, Becht E, Hansi NK, Foster GR, Su TH, Tseng TC, Lim SG, Kao JH, Newell EW, Kennedy PT*, Bertoletti A*. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. J Clin Invest. 2018 Feb 1;128(2):668-681. doi: 10.1172/JCI92812
• Bertoletti A, Kennedy PTF, Durantel D. HBV infection and HCC: the 'dangerous liaisons'. Gut 2018 May;67(5):787-788. doi: 10.1136/gutjnl-2017-315528.
• Singh HD, Otano I, Rombouts K, Singh KP, Peppa D, Gill US, Böttcher K, Kennedy PTF, Oben J, Pinzani M, Walczak H, Fusai G, Rosenberg WMC, Maini MK. TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis. Sci Rep. 2017 Jul 17;7(1):5514. doi: 10.1038/s41598-017-05845-5.
• Gill US, Kennedy PTF. Current therapeutic approaches for HBV infected patients. J Hepatol. 2017 Aug;67(2):412-414. doi: 10.1016/j.jhep.2017.04.015.
• Duriez M, Mandouri Y, Lekbaby B, Wang H, Schnuriger A, Redelsperger F, Guerrera CI, Lefevre M, Fauveau V, Ahodantin J, Quetier I, Chhuon C, Gourari S, Boissonnas A, Gill U, Kennedy PT, Debzi N, Sitterlin D, Maini MK, Kremsdorf D, Soussan P. Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity. J Hepatol. 2017 Oct;67(4):687-699. doi: 10.1016/j.jhep.2017.05.025.
• Pallett LJ, Davies J, Colbeck EJ, Robertson F, Hansi N, Easom NJW, Burton AR, Stegmann KA, Schurich A, Swadling L, Gill US, Male V, Luong T, Gander A, Davidson BR, Kennedy PTF, Maini MK. IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection. J Exp Med. 2017 Jun 5;214(6):1567-1580. doi: 10.1084/jem.20162115. doi: 10.1084/jem.20162115.
• Kennedy PTF, Litwin S, Dolman GE, Bertoletti A, Mason WS. Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. Viruses. 2017 Apr 29;9(5). pii: E96. doi: 10.3390/v9050096.
• Salpini R, Piermatteo L, Gill US, Battisti A, Stazi F, Guenci T, Giannella S, Serafini V, Kennedy PTF, Perno CF, Svicher V, Ciotti M. Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS® Ampliprep/COBAS®TaqMan HBV test v2.0. Med Microbiol Immunol. 2017 Aug;206(4):295-299. doi: 10.1007/s00430-017-0504-3.
• Kennedy PTF, Bertoletti A, Mason WS. Reply. Gastroenterology. 2017 Apr;152(5):1246-1247. doi: 10.1053/j.gastro.2017.03.002.
• Huang WC, Easom NJ, Tang XZ, Gill US, Singh H, Robertson F, Chang C, Trowsdale J, Davidson BR, Rosenberg WM, Fusai G, Toubert A, Kennedy PT, Peppa D, Maini MK. T Cells Infiltrating Diseased Liver Express Ligands for the NKG2D Stress Surveillance System. J Immunol. 2016 Dec 28. pii: 1601313. doi: 10.4049/jimmunol.1601313. doi: 10.4049/jimmunol.1601313.
• Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK*, Kennedy PT*. Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo. PLoS Pathog. 2016 Aug 3;12(8):e1005788. doi: 10.1371/journal.ppat.1005788. eCollection 2016 Aug.
• Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, Hong ML, Naik S, Quaglia A, Bertoletti A, Kennedy PT. HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. Gastroenterology. 2016 Nov;151(5):986-998. doi: 10.1053/j.gastro.2016.07.012.
• Schurich A, Pallett LJ, Jajbhay D, Wijngaarden J, Otano I, Gill US, Hansi N, Kennedy PT, Nastouli E, Gilson R, Frezza C, Henson SM, Maini MK. Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host. Cell Rep. 2016 Aug 2;16(5):1243-52. doi: 10.1016/j.celrep.2016.06.078.
• Stegmann KA, Robertson F, Hansi N, Gill U, Pallant C, Christophides T, Pallett LJ, Peppa D, Dunn C, Fusai G, Male V, Davidson BR, Kennedy PT, Maini MK. CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural killer cells residing in human liver. Sci Rep. 2016 May 23;6:26157. doi: 10.1038/srep26157.
• Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, Kennedy PT, Dusheiko G, Hill-Cawthorne G, Thomas H. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom. Value Health. 2015 Sep;18(6):800-9. doi: 10.1016/j.jval.2015.05.007.
• Pallett LJ, Gill US, Quaglia A, Sinclair LV, Jover-Cobos M, Schurich A, Singh KP, Thomas N, Das A, Chen A, Fusai G, Bertoletti A, Cantrell DA, Kennedy PT, Davies NA, Haniffa M, Maini MK. Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. Nat Med. 2015 Jun;21(6):591-600. doi: 10.1038/nm.3856.
• El Bouzidi K, Elamin W, Kranzer K, Irish DN, Ferns B, Kennedy PT, Rosenberg W, Dusheiko G, Sabin CA, Smith BC, Nastouli E. Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London. J Clin Virol. 2015 May;66:33-7. doi: 10.1016/j.jcv.2015.02.011
• Gill US, Kennedy PT. New insights in the management of chronic hepatitis B. Clin Med (Lond). 2015 Apr;15(2):191-6. doi: 10.7861/clinmedicine.15-2-191.
• Bertoletti A, Kennedy PT. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol. 2015 May;12(3):258-63. doi: 10.1038/cmi.2014.79.
• Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJ, Barr DA, Kallis YN, Marley RT, Kooner P, Foster GR, Kennedy PT. Assessment of Bone Mineral Density in Tenofovir treated Chronic Hepatitis B patients: Can FRAX identify those at greatest risk? J Infect Dis. 2015 Feb;211(3):374-82. doi: 10.1093/infdis/jiu471.
• Gill US, Kennedy PT. Chronic hepatitis B virus in young adults: the need for new approaches to management. Expert Rev Anti Infect Ther. 2014 Sep;12(9):1045-53.10.1586/14787210.2014.940899.
• Jo J, Tan AT, Ussher JE, Sandalova E, Tang XZ, Tan-Garcia A, To N, Hong M, Chia A, Gill US, Kennedy PT, Tan KC, Lee KH, De Libero G, Gehring AJ, Willberg CB, Klenerman P, Bertoletti A. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog. 2014 Jun 26;10(6):e1004210. doi: 10.1371/journal.ppat.1004210. eCollection 2014 Jun.
• Gehring AJ, Haniffa M, Kennedy PT, Ho ZZ, Boni C, Shin A, Banu N, Chia A, Lim SG, Ferrari C, Ginhoux F, Bertoletti A. Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J Clin Invest. 2013 Sep 3;123(9):3766-76. doi: 10.1172/JCI66043
• Sarri G, Westby M, Bermingham S, Hill-Cawthorne G, Thomas H; Guideline Development Group. Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance. BMJ. 2013 Jun 26;346:f3893. doi: 10.1136/bmj.f3893.
• Schurich A, Pallett LJ, Lubowiecki M, Singh HD, Gill US, Kennedy PT, Nastouli E, Tanwar S, Rosenberg W, Maini MK. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cells. PLoS Pathog. 2013 Mar;9(3):e1003208. doi: 10.1371/journal.ppat.1003208.
• Peppa D, Gill US, Reynolds G, Easom NJ, Pallett LJ, Schurich A, Micco L, Nebbia G, Singh HD, Adams DH, Kennedy PT, Maini MK. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell mediated deletion. J Exp Med. 2013 Jan 14;210(1):99-114. doi: 10.1084/jem.20121172.
• Nebbia G, Peppa D, Schurich A, Khanna P, Singh HD, Cheng Y, Rosenberg W, Dusheiko G, Gilson R, ChinAleong J, Kennedy PT, Maini MK. Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One. 2012;7(10):e47648. doi: 10.1371/journal.pone.0047648.
• Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, Chen A, Blair P, Dusheiko G, Gill US, Kennedy PT, Brunetto M, Lampertico P, Mauri C, Maini MK. IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol. 2012 Oct 15;189(8):3925-35. doi: 10.4049/jimmunol.1103139.
• Kennedy PT, Sandalova E, Jo J, Gill US, Ushiro-Lumb I, Tan AT, Naik S, Foster GR, Bertoletti A. Preserved T cell function in children and young adults with immune tolerant chronic hepatitis B. Gastroenterology. 2012 Sep;143(3):637-45. doi: 10.1053/j.gastro.2012.06.009.
• Ji C, Sastry KS, Tiefenthaler G, Cano J, Tang T, Ho ZZ, Teoh D, Bohini S, Chen A, Sankuratri S, Macary PA, Kennedy PT, Ma H, Ries S, Klumpp K, Kopetzki E, Bertoletti A. Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies. Hepatology. 2012 Dec;56(6):2027-38. doi: 10.1002/hep.25875.
• Liu M, Miao T, Zhu H, Symonds AL, Li L, Schurich A, Maini MK, Zhang J, Kennedy PT, Li S, Wang P. IL-2-engineered nano-APC effectively activates viral antigen-mediated T cell responses from chronic hepatitis B virus-infected patients. J Immunol. 2012 Feb;188(3):1534-43. doi: 10.4049/jimmunol.1102709.
• Malik R, Kennedy PT, Suri D, Brown A, Goldin R, Main J, Thomas H, Thursz M. The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience. Hepat Res Treat. 2011;2011:524027. doi: 10.1155/2011/524027.
• Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, Nebbia G, Kennedy PT, Geretti AM, Dusheiko G, Maini MK. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology. 2011 May;53(5):1494-503. doi: 10.1002/hep.24249.
• Sastry KS, Too CT, Kaur K, Gehring AJ, Low L, Javaid A, Pollicino T, Li L, Kennedy PT, Lopatin U, Macary PA, Bertoletti A. Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody. J Virol. 2011 Mar;85(5):1935-42. doi: 10.1128/JVI.01990-10.
• Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, Dunn C, Pallant C, Ellis G, Khanna P, Dusheiko G, Gilson RJ, Maini MK. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog. 2010 Dec 16;6(12):e1001227. doi: 10.1371/journal.ppat.1001227.
• Kennedy PT, Russo E, Kumar N, Powell N, Bansi D, Thillainayagam A, Vlavianos P, Westaby D. The safety and utility of prophylactic pancreatic duct stents in the prevention of post-ERCP pancreatitis: an analysis of practice in a single UK tertiary referral center. Surg Endosc. 2010 Aug;24(8):1923-8. doi: 10.1007/s00464-009-0875-7.
• Pasha Y, Blunt D, Kennedy PT. The pea, the yeast and the prostate. QJM. 2010 Apr;103(4):265-6. doi: 10.1093/qjmed/hcp160
• Kennedy PT, Gehring AJ, Nowbath A, Selden C, Quaglia A, Dhillon A, Dusheiko G, Bertoletti A. The expression and function of NKG2D molecule on intrahepatic CD8+ T cells in chronic viral hepatitis. J Viral Hepat. 2008 Dec;15(12):901-9. doi: 10.1111/j.1365-2893.2008.01049
• Kennedy PT, Lee HC, Jeyalingam L, Malik R, Karayiannis P, Muir D, Main J, Thursz M, Goldin R, Smith B, Brown A, Thomas HC. NICE guidelines and a treatment algorithm for the management of chronic hepatitis B: a review of 12 years experience in west London. Antivir Ther. 2008;13(8):1067-76.
• Das A, Hoare M, Davies N, Lopes AR, Dunn C, Kennedy PT, Alexander G, Finney H, Lawson A, Plunkett FJ, Bertoletti A, Akbar AN, Maini MK. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med. 2008 Sep 1;205(9):2111-24. doi: 10.1084/jem.20072076.
• Kennedy PT, Phillips N, Chandrasekhar J, Jacobs R, Jacobs M, Dusheiko G. Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping. Liver Int. 2008 May;28(5):699-704. doi: 10.1111/j.1478-3231.
• Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertoletti A, Maini MK. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med. 2007 Mar 19;204(3):667-80
• Gehring AJ, Sun D, Kennedy PT, Nolte-'t Hoen E, Lim SG, Wasser S, Selden C, Maini MK, Davis DM, Nassal M, Bertoletti A. The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J Virol. 2007 Mar;81(6):2940-9.
• Kennedy PT, Zakaria N, Modawi SB, Papadopoulou AM, Murray-Lyon I, du Bois RM, Jervoise N Andreyev H, Devlin J. Natural history of hepatic sarcoidosis and its response to treatment. Eur J Gastroenterol Hepatol. 2006 Jul;18(7):721-6.
• Kennedy PT, Urbani S, Moses RA, Amadei B, Fisicaro P, Lloyd J, Maini MK, Dusheiko G, Ferrari C, Bertoletti A. The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology. 2006 Mar;43(3):602-11.
• Franzese O, Kennedy PT, Gehring AJ, Gotto J, Williams R, Maini MK, Bertoletti A. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol. 2005 Mar;79(6):3322-8.
• BOOKS/BOOK CHAPTERS
• Textbook of Hepatogastroenterology, Volume 1, Hepatology. Atlas Publishers 2016. Zakaria S & Kennedy PT (Editor)
• Hansi N, Gill US, Kennedy PT. Chapter 10; Chronic Hepatitis B. Liver Disease in Clinical Practice; Springer (2017)
• Koffas A, Kennedy PT. Chapter 16, liver disease. In C. Whittlesea & K. Hodson (Eds.), Clinical Pharmacy and Therapeutics (6th ed., pp. 258-277). Elsevier (2019).
• Koffas A, Gill US, Kennedy PT. Chapter 33, hepatitis B: prognosis and treatment. In J.W.D. McDonald, B.G. Feagan, R. Jalan & P.J. Kahrilas (Eds.). Evidence-Based Gastroenterology and Hepatology (4th ed., pp. 490-499). John Wiley & Sons Ltd (2019).
• Kennedy PT. et al. The Liver, Sarcoidosis. Hodder Arnold Publishers, 1st Ed (2012).
• Kennedy PT, O’Grady, J. Liver Disease. In: Walker and Whittlesea, Clinical Pharmacy and Therapeutics. Oxford: Churchill Livingstone; 5th Edition, (2011).
• Bertoletti A, Kennedy PT, Gehring A. Role of the immune response in hepatitis B: determinants of severity, chronicity and response to antiviral therapy. Liver Immunology Principles and Practice. Gershwin, Vierling and Manns. Humana Press 2007:179-193.

...

Professional membership

• HEFCE Clinical Senior Lectureship Award (2009)

Languages spoken

English